Ocean Biomedical, Inc. (OCEA)
NASDAQ: OCEA · Real-Time Price · USD
0.664
+0.075 (12.75%)
At close: Dec 20, 2024, 4:00 PM
0.619
-0.045 (-6.73%)
After-hours: Dec 20, 2024, 7:40 PM EST

Ocean Biomedical Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Ocean Biomedical.

Analyst Consensus: n/a
Target Low Average Median High
Price n/a n/a n/a n/a
Change n/a n/a n/a n/a

Analyst Ratings

There are currently no analyst ratings available for OCEA.

Recommendation Trends

Rating Apr '23May '23
Strong Buy 20
Buy 00
Hold 00
Sell 00
Strong Sell 00
Total 20

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Taglich Brothers
Taglich Brothers
Buy
Initiates
$20
Buy Initiates $20 +2,911.59% May 31, 2023
EF Hutton
EF Hutton
Strong Buy
Initiates
$17
Strong Buy Initiates $17 +2,459.86% May 25, 2023
EF Hutton
EF Hutton
Strong Buy
Maintains
$10$17
Strong Buy Maintains $10$17 +2,459.86% Apr 27, 2023
EF Hutton
EF Hutton
Strong Buy
Reiterates
$10
Strong Buy Reiterates $10 +1,405.80% Apr 13, 2023
Fundamental Research Corp.
Fundamental Research Corp.
Strong Buy
Initiates
$16
Strong Buy Initiates $16 +2,369.51% Mar 16, 2023
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.91
from -4.35
EPS Next Year
n/a
from -0.91
Fiscal Year FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024
Period Ending Dec 31, 2019 Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024
Revenue
------
Revenue Growth
------
EPS
-0.01-0.09-3.57-0.74-4.35-0.91
EPS Growth
------
Forward PE
------
No. Analysts -----3
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 2024
High n/a
Avg n/a
Low n/a

Revenue Growth

Revenue Growth 2024
High -
Avg -
Low -

EPS Forecast

EPS 2024
High -0.93
Avg -0.91
Low -0.87

EPS Growth

EPS Growth 2024
High -
Avg -
Low -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.